Advertisement


Christopher R. Kelsey, MD, on DLBCL: Study Results on Consolidation Radiotherapy

2017 ASTRO Annual Meeting

Advertisement

Christopher R. Kelsey, MD, of Duke University Medical Center, discusses reducing the radiation dose from 30 Gy to 20 Gy for patients with diffuse large B-cell lymphoma. Phase II findings show this approach may be effective in light of improved systemic treatment and better chemotherapy response assessment (Presentation 298).



Related Videos

Survivorship

James E. Bates, MD, on Pediatric Cancer Survivors: New Findings on Late Effects

James E. Bates, MD, of the University of Florida, discusses a volumetric dose-effect analysis of late cardiotoxicity, results from the Childhood Cancer Survivor Study (Abstract 4).

Prostate Cancer

William A. Hall, MD, on Prostate Cancer: Results From a Study of Three Treatment Modalities

William A. Hall, MD, of the Medical College of Wisconsin, discusses trial findings on androgen deprivation and radiation alone, compared with androgen deprivation, radiotherapy, and surgery in men with high-risk, nonmetastatic adenocarcinoma of the prostate (Abstract 15).

Prostate Cancer

Juanita Crook, MD, on Prostate Cancer: Results From an NRG/RTOG Brachytherapy Trial

Juanita Crook, MD, of the University of British Columbia, discusses late toxicity findings on transperineal ultrasound–guided brachytherapy for locally recurrent prostate cancer after external-beam radiation therapy (Abstract 1).

Prostate Cancer
Kidney Cancer

Gerard Morton, MD, on GU Highlights: Expert Perspective

Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).

Lung Cancer

Jeffrey D. Bradley, MD, on NSCLC: Results of the RTOG 0617 Trial

Jeffrey D. Bradley, MD, of Washington University School of Medicine, discusses long-term phase III findings on standard-dose vs high-dose conformal chemoradiation therapy with or without cetuximab for stage III non–small cell lung cancer (Abstract 227).

Advertisement

Advertisement




Advertisement